4 ms·
It points it out as being an unwise regulation with bad price consequences. It does state that other governments set price controls in various ways - like the
by Broken_Hippo 10y ago
It points it out as being an unwise regulation with bad price consequences.
It does state that other governments set price controls in various ways - like the UK refusing to pay for a drug if it doesn't meet cost-effectiveness.. though I'm not sure how exactly that winds up affecting which drugs are available and which aren't.
Then the actual reason for the listed example is that it makes sure folks are covered for some things. Rules for coverage in itself doesn't raise prices. And when these are the things they highlight as soft spots in the regulation system instead of focusing more on the non-negotiations, the systems itself, the money on advertising, and other such things, to me it comes down to having a weird slant or poorly thought out.
- DanBC 10y ago> It does state that other governments set price controls in various ways - like the UK refusing to pay for a drug if it doesn't meet cost-effectiveness.. though I'm not sure how exactly that winds up affecting which drugs are available and which aren't. The UK (strictly, English, because health is devolved in Scotland and in Wales) is tricky. There's an independent organisation called NICE who look at cost effectiveness. I think Abraxane, a pancreatic cancer chemotherapy, is a useful example. Currently there are two chemotherapies. Neither is particularly effective. One is slightly more effective, but has a lot of side effects. The other is slightly less effective, but has fewer side effects. For Abraxane to get funding it has to be more effective than either of these meds. It isn't. Or it needs to have fewer side effects. It doesn't. It has the sub-optimal combination of the same high side effects as one of the existing meds with the reduced efficiacy of the other med, while being more expensive than both of them. So, NICE recommend that it's not used. That means that Clinical Commissioning Groups probably aren't going to pay for it. That means that if people really want to use it they either pay for it privately, or they use their medical insurance (if they have any) to get it. But insurance companies probably aren't going to pay for it, because they're using similar cost effective calculations as NICE. NICE gives special consideration to end of life medication, but even with these special considerations abraxane was not cost effective. (There used to be a thing that people buying these very expensive and not effective cancer meds would have to also pay for the rest of their health care privately. I'm not sure if that's still the case. It was an attempt to stop abusive drug companies from exploiting dying people and their families who were sometimes selling their homes to pay for ineffective meds.) Press release: https://www.nice.org.uk/news/press-and-media/nice-publishes-final-draft-guidance-on-nab-paclitaxel-abraxane-for-pancreatic-cancer https://www.nice.org.uk/news/press-and-media/nice-publishes-... The actual guidance, which is pretty comprehensive about how they reach their decision: https://www.nice.org.uk/guidance/TA360 https://www.nice.org.uk/guidance/TA360
- shermozle 10y ago> UK refusing to pay for a drug if it doesn't meet cost-effectiveness.. though I'm not sure how exactly that winds up affecting which drugs are available and which aren't. It means the supplier has a choice: meet the cost effectiveness model's price, or earn almost no money in that market. It's a powerful tool and run quite transparently. Look up the National Institute for Clinical Excellence. There is occasionally some political blowback that distorts the purity of it, but generally it works pretty well.